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Abstract
Approximately one-third of the patients with well-differentiated liposarcoma (WDLPS) will
develop a local recurrence. Not much is known about the molecular relationship between
the primary tumor and the recurrent tumor, which is important to reveal potential drivers of
recurrence. Here we investigated the biology of recurrent WDLPS by comparing paired pri-
mary and recurrent WDLPS using microRNA profiling and genome-wide DNA methylation
analyses. In total, 27 paired primary and recurrent WDLPS formalin-fixed and paraffin-
embedded tumor samples were collected. MicroRNA expression profiles were determined
using TaqMan® Low Density Array (TLDA) cards. Genome-wide DNA methylation and dif-
ferentially methylated regions (DMRs) were assessed by methylated DNA sequencing
(MeD-seq). A supervised cluster analysis based on differentially expressed microRNAs
between paired primary and recurrent WDLPS did not reveal a clear cluster pattern separat-
ing the primary from the recurrent tumors. The clustering was also not based on tumor locali-
zation, time to recurrence, age or status of the resection margins. Changes in DNA
methylation between primary and recurrent tumors were extremely variable, and no consis-
tent DNA methylation changes were found. As a result, a supervised clustering analysis
based on DMRs between primary and recurrent tumors did not show a distinct cluster pat-
tern based on any of the features. Subgroup analysis for tumors localized in the extremity or
the retroperitoneum also did not yield a clear distinction between primary and recurrent
WDLPS samples. In conclusion, microRNA expression profiles and DNA methylation pro-
files do not distinguish between primary and recurrent WDLPS and no putative common
drivers could be identified.
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Introduction
Soft tissue sarcomas form a heterogeneous group of rare, mesenchymal tumors, of which lipo-
sarcomas comprise one of the largest subgroups.[1] Of all 100–120 patients diagnosed annually
with liposarcoma in the Netherlands[2], the most common subtype is well-differentiated lipo-
sarcoma (WDLPS). WDLPS are mostly localized in the extremities and the retroperitoneum,
and the prognosis of these patients is significantly better than those of patients with dedifferen-
tiated liposarcoma.[2] However, WDLPS have a risk of dedifferentiation, potentially leading to
metastatic disease with concurrent dismal prognosis. The rate of dedifferentiation in WDLPS
in the extremities is extremely low, while in the retroperitoneum the risk of dedifferentiation is
higher.[1] Molecularly, WDLPS are characterized by amplification–on a neochromosome–of
the 12q14-15 region, which includes the genes MDM2 and CDK4.[1] Treatment of WDLPS
consists of complete surgical resection of the tumor, occasionally combined with neoadjuvant/
adjuvant radiotherapy for tumors localized in the retroperitoneum. Unfortunately, approxi-
mately one-third of the patients will develop a local recurrence. Whereas the biology and
behavior of primary WDLPS has been widely studied, there is a lack of insight in changes in
microRNA expression and DNA methylation profiles between primary and recurrent
WDLPS.
MicroRNAs have been proven to play a significant role in tumorigenesis[3–5], including in
soft tissue sarcomas and more specifically liposarcomas.[6–11] So far, microRNA expression
profiles have been used to differentiate between different liposarcoma subtypes[6–9, 12, 13] or
to predict patient outcome.[10, 11, 14, 15] However, it is unclear whether primary WDLPS
and their recurrent tumors can be distinguished by their microRNA profiles, which would sug-
gest that microRNAs may be involved in the process of recurrence.
DNA methylation is an epigenetic process that fulfils an essential role in physiological and
biological processes[16], and can be an important pathological driver in cancer.[17, 18] DNA
methylation patterns can be utilized as biomarker[19, 20], to classify cancer (sub)types[21, 22]
or to predict outcome.[20, 23] Genome-wide DNA methylation analysis used to be technically
challenging and costly, but recently a new method was developed showing accurate genome-
wide analysis of CpG-methylation by using the DNA methylation-dependent restriction
enzyme LpnPI and subsequent DNA sequencing of the restriction fragments.[24] This methyl-
ated DNA sequencing (MeD-seq) technology is cost-effective, accurate and reproducible with
high coverage, suitable for high-throughput epigenetic profiling, even on FFPE material. For
liposarcoma in general and recurrent WDLPS specifically, the knowledge of epigenetics is lim-
ited. Only a few studies report on the role of DNA methylation in liposarcomas, but mostly
focus on one specific DNA region in more aggressive liposarcomas subtypes.[25, 26] Some
studies report a link between DNA methylation and microRNAs, for example methylation-
induced silencing of miR-193b in dedifferentiated liposarcoma but not in WDLPS[27] and
low expression of miR-193b, due to downregulation by promoter methylation, resulting at
least partly from an increased expression of DNA methyltransferase-1.[28]
In this study, we molecularly compared primary and recurrent WDLPS at microRNA and
DNA methylation level aiming to discover differences and/or similarities that give insight in
the biology of recurrent WDLPS.
Materials and methods
Patients and samples
Patients with available tumor samples of a primary and matching first recurrent WDLPS who
were treated with surgery only were included. The formalin-fixed and paraffin-embedded
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(FFPE) tissue blocks were obtained through PALGA, the Dutch nationwide pathology registry,
and the pathology department of the Maria Skłodowska-Curie Institute-Oncology Center
together with anonymized clinicopathological information. The resection margins were
defined as R0 (microscopically negative margins), R1 (microscopically positive margins), R2
(macroscopically positive margins) or Rx (unknown/not assessed). Although recurrence after
R1/R2 resections can be considered as progressed WDLPS rather than truly recurrent
WDLPS, these will be referred to as recurrent WDLPS as well. To calculate time to recurrence,
the resection dates stated in the pathology reports were used. Each pair received an individual
number with index numbers designating the primary tumor (.1) or recurrent tumor (.2).
The experimental protocol was reviewed and approved by the Medical Ethics Committee of
the Erasmus MC (MEC-2016-213). All experimental procedures were performed in accor-
dance with the relevant guidelines and regulations, including the Helsinki Declaration. The
use of anonymous or coded left-over material for scientific purposes is part of the standard
treatment agreement with patients and therefore additional informed consent was not asked.
RNA and DNA isolation
The archival tumor samples were examined by an expert pathologist to confirm the initial his-
topathological diagnosis and to determine the percentage of tumor cells. The diagnosis of
WDLPS was based either on the presence of lipomatous cells with fibrous septa and spindle
cells with hyperchromatic irregular nuclei, or on the amplification of the MDM2-gen using
FISH in case morphological atypia was less conspicuous. Only sections containing approxi-
mately 100% tumor cells were used for isolation. Total RNA was isolated using the RecoverAll™
Total Nucleic Acid Isolation Kit (Ambion/Life Technologies) and total DNA was isolated
using the AllPrep1DNA/RNA FFPE kit (Qiagen), both according to manufacturer’s
instructions.
MicroRNA expression profiling
MicroRNA expression was determined using TaqMan1 Low Density Array (TLDA) cards (A
card v2.0, B card v3.0, Applied Biosystems/Thermo Fisher Scientific). Megaplex™ RT Primers
(Human Pool, pool A v2.1, pool B v3.0, Applied Biosystems/Thermo Fisher Scientific) were
used for cDNA synthesis, followed by a standard pre-amplification protocol using Megaplex™
PreAmp Primers (Human Pool, pool A v2.1, pool B v3.0, Applied Biosystems/Thermo Fisher
Scientific). The TLDA cards were analysed using a 7900HT Real-Time PCR system (Applied
Biosystems). The paired samples were processed in three batches for logistical and technical
reasons, with each primary and its matching recurrent tumor being placed within the same
batch.
Statistical analysis of microRNA profiling data
The expression of each microRNA in a sample was normalized to the median Ct-value of all
detectable microRNAs in that sample. The normalized relative expression was subsequently
calculated for each microRNA and log-transformed. Since the samples were processed in mul-
tiple batches, potential batch-effects were investigated using PCA-plots in R (S1 Fig). To cor-
rect for the observed batch-effects, ComBat was used[29]. Only microRNAs detected in at least
50% of the samples were included in the statistical analyses. A paired t-test was performed to
identify microRNAs that were differentially expressed between paired primary and recurrent
WDLPS samples. A two-sided p-value <0.05 was considered statistically significant. To
adjust for multiple testing, a false discovery rate (FDR) of 0.25 was used. For all microRNA
clustering analyses, the software program Cluster 3.0 was used followed by Java TreeView for
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visualization of the clustering results. The microRNA expression datasets generated and ana-
lysed during the current study have been deposited to the Gene Expression Omnibus (GEO)
data repository under submission number GSE137722.
MeD-seq sample preparations
MeD-seq analyses were essentially carried out as previously described[24]. DNA samples were
digested by LpnPI (New England Biolabs). Stem-loop adapters were blunt-end ligated to
repaired input DNA and amplified to include dual indexed barcodes using a high fidelity poly-
merase to generate an indexed Illumina NGS library. The amplified end product was purified
on a Pippin HT system with 3% agarose gel cassettes (Sage Science). Multiplexed samples were
sequenced on Illumina HiSeq2500 systems for single reads of 50bp according to manufactur-
er’s instructions. Dual indexed samples were demultiplexed using bcl2fastq software
(Illumina).
MeD-seq data analysis
Data processing was carried out using specifically created scripts in Python. Raw fastq files
were subjected to Illumina adaptor trimming and reads were filtered based on LpnPI restric-
tion site occurrence between 13-17bp from either 5’ or 3’ end of the read and mapped to hg38
using bowtie2. Genome-wide individual LpnPI site scores were used to generate read count
scores for the following annotated regions (www.ensembl.org): transcription start sites (TSS, 1
kb before and 1 kb after), CpG-islands and gene bodies (1kb after TSS till TES). Detection of
differentially methylated regions (DMRs) was performed between two datasets using the
χ2-test on read counts. Significance was called by either Bonferroni or FDR using the Benja-
mini-Hochberg procedure.
In addition, a genome-wide sliding window was used to detect sequentially differentially
methylated LpnPI sites. Statistical significance was called between LpnPI sites in predeter-
mined groups using the χ2-test. Neighboring significantly called LpnPI sites were binned and
reported. Annotation of the overlap was reported for TSS, CpG-islands and gene body regions.
DMR thresholds were based on LpnPI site count, DMR sizes (in bp) and fold changes of read
counts as mentioned in the figure legends before performing hierarchical clustering. The dif-
ferentially methylated datasets generated and analyzed during the current study have been
deposited to the Sequence Read Archive (SRA) under submission number PRJNA574561.
Results
Patient samples
In total 27 pairs of patient samples were collected: 16 from the Erasmus MC Cancer Institute,
9 from the Netherlands Cancer Institute, and 2 from the Maria Skłodowska-Curie Institute-
Oncology Center. The extremity was the most common localization (N = 15), followed by the
retroperitoneum (N = 8). Fourteen patients were female, 13 patients were male. The median
age at time of diagnosis of the primary tumor was 59 years (interquartile range [IQR] 50–64)
and the median time to recurrence was 3.7 years (IQR 1.9–6.5). In a number of patients
(N = 8, 29.6%), the status of the resection margins of the primary tumor was unknown, not
assessed or not specified (Rx) in the pathology report. Of those patients of whom the status of
the resection margins was reported, all primary resections were R0 or R1 resections, except for
one patient (no. 17) with tumor localization in the esophagus, who underwent a R2 resection.
Resections of the recurrent tumors resulted in 4 patients in R2 resections (Table 1).
Primary versus recurrent well-differentiated liposarcoma
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Table 1. Patient and tumor characteristics.
Sample Age† Sex Localization Resection margins Time to recurrence‡ No. of DMRs
1.1 64 Female Upper leg R1 3.7 32,854
1.2 68 R1
2.1 78 Male Retroperitoneal R1 1.9 2,430
2.2 79 R2
3.1 58 Female Upper leg R1 10.6 4,410
3.2 69 R1
4.1 50 Male Upper leg Rx 8.3 1,061
4.2 59 R2
5.1 62 Male Axilla R0 5.3 1,191
5.2 67 Rx
6.1 31 Female Upper leg R1 8.5 2,732
6.2 39 R0
8.1 60 Male Lower leg Rx 1.0 724
8.2 61 Rx
9.1 38 Female Upper leg R1 2.1 675
9.2 40 R1
10.1 68 Female Mediastinum R0 1.3 1,747
10.2 69 R1
11.1 52 Female Retroperitoneal Rx 2.6 1,028
11.2 54 Rx
13.1 50 Female Retroperitoneal R1 8.1 3,659
13.2 58 R1
14.1 64 Male Upper leg R0 0.6 636
14.2 64 R1
15.1 55 Female Retroperitoneal R1 2.0 1,920
15.2 57 R1
16.1 48 Male Lower leg R1 0.4 473
16.2 48 R1
17.1 70 Male Esophagus R2 0.1 586
17.2 70 R2
19.1 43 Male Upper leg R1 4.7 7,644
19.2 48 R1
20.1 64 Male Upper leg R1 6.5 21,585
20.2 70 R1
21.1 52 Male Retroperitoneal R0 3.5 1,481
21.2 56 R0
22.1 59 Female Retroperitoneal Rx 4.2 314
22.2 63 R1
23.1 47 Male Upper leg R1 16.6 1,119
23.2 63 R0
24.1 76 Female Upper leg R1 3.0 372
24.2 79 R0
25.1 49 Female Upper leg Rx 3.9 482
25.2 53 R1
26.1 50 Female Retroperitoneal Rx 2.1 2,513
26.2 53 Rx
(Continued)
Primary versus recurrent well-differentiated liposarcoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0228014 January 23, 2020 5 / 16
MicroRNA profiling of paired primary–recurrent WDLPS samples
After correction for batch effect, samples 10.1 and 10.2 were excluded from further microRNA
analyses (S1 Fig). First, an unsupervised hierarchical clustering analysis was performed to
group the samples based on their microRNA expression profiles without prior knowledge of
the origin of the sample (primary or recurrent). This clustering did not show a clear distinction
between primary and recurrent WDLPS samples, neither a discriminative pattern based on
tumor localization, time to recurrence, age nor the status of the resection margins could be
observed (Fig 1A). In 9 of the 26 pairs, the primary and recurrent tumor samples clustered
together (indicated by the red squares in the bottom row of the figure). All of these pairs had a
short time to recurrence (before the median time to recurrence of 3.7 years), except one pair
with a time to recurrence of 3.9 years and one pair with a time to recurrence of 6.1 years.
Next, a supervised analysis was performed based on the expression levels of the 28 signifi-
cant differentially expressed microRNAs (p<0.05, FDR<0.25)(Fig 1B, S1 Table). The heat
map indicated no clear discriminative pattern between primary and recurrent WDLPS, nor a
distinction based on tumor localization, time to recurrence, age or the status of the resection
margins. Five pairs clustered together, but clustering of these pairs also did not seem to be
driven by one of the clinicopathological parameters.
Since microRNA expression is reported to be (partially) tissue specific[30], it may be influ-
enced by the localization of the tumor. Therefore, additional sub-analyses for the two largest sub-
groups regarding tumor localization were performed: the extremity (N = 15 pairs, Fig 2A) and
the retroperitoneum (N = 8 pairs, Fig 2B). For the tumor samples localized in the extremity, 68
microRNAs were significantly differentially expressed between primary and recurrent WDLPS
of which 9 had an FDR<0.25 (Fig 2A, S2 Table). A cluster analysis based on the expression of
these microRNAs did not seem to depend on primary/recurrence, time to recurrence, age or sta-
tus of the resection margins. For the retroperitoneal WDLPS, only 14 microRNAs were signifi-
cantly differentially expressed, of which none had an FDR<0.25 (S2 Table). Therefore, the
microRNAs with p<0.05 without FDR correction were used to generate a heat map for this sub-
group (Fig 2B). Again, no distinction between primary and recurrent samples was observed.
DNA methylation patterns of paired primary–recurrent WDLPS samples
When comparing differentially methylated DNA regions (DMRs) between individual primary
and recurrent WDLPS pairs, it was noted that the DNA methylation differences were
Table 1. (Continued)
Sample Age† Sex Localization Resection margins Time to recurrence‡ No. of DMRs
27.1 60 Male Retroperitoneal Rx 1.5 1,377
27.2 61 R1
28.1 71 Female Upper leg R0 6.1 1,910
28.2 77 R1
29.1 60 Male Trunk Rx 13.8 2,819
29.2 74 R1
30.1 61 Female Upper leg R1 4.6 294
30.2 66 R2
DMR: differentially methylated region.
†Age at time of surgery.
‡in years
https://doi.org/10.1371/journal.pone.0228014.t001
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Fig 1. Hierarchical clustering based on the microRNA expression levels of 26 paired primary and recurrent WDLPS tumor samples. (A) Results of an
unsupervised clustering analysis, depicted with time to recurrence, tumor localization, age and the status of the resection margins. Tumor pairs that cluster together in
the same branch of the cluster tree are indicated with red boxes in the bottom line of the figure. (B) Results of a supervised clustering analysis based on the expression of
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extremely variable between pairs (Table 1), although most of the pairs with a short time to
recurrence (before median time to recurrence of 3.7 years) tended to have a lower number of
DMRs. However, samples with a longer time to recurrence, for example sample pairs 23 and
28, also displayed relative low numbers of DMRs, and sample pair 1, which had a short time to
recurrence, exhibited the largest number of DMRs (Table 1). These DNA methylation differ-
ences seemed to be inconsistent among the individual pairs and could not be identified when
comparing primary tumors versus recurrent tumors as a group. In the total group, only a rela-
tively small number of 470 DMRs were identified, located on various chromosomes (S3
Table). When these DMRs were used for a supervised hierarchical clustering analysis, no clear
clustering of the 27 primary and recurrent samples was observed (Fig 3). Likewise, no distinc-
tion was detected based on the clinicopathological parameters (Fig 3). Five of the pairs clus-
tered together, but again across these samples no similarities in terms of time to recurrence,
localization, or the status of the resection margins could be identified.
A relatively high number of the observed 470 DMRs was located at chromosome 12 (S3
Table), including DMRs linked to the genes MDM2, CDK4 and MIR26A (S4 Table). These
DMRs might indicate a possible difference in methylation of (regions of) chromosome 12
between primary and recurrent WDLPS, albeit the fold changes between the groups are rela-
tively low (S4 Table). The highest fold change observed was 2.03 for the gene RP11-611E13.2, a
relatively unknown gene located on chr12q15, the same region as MDM2, encoding a non-
coding RNA. For MDM2, which is amplified in WDLPS, eight DMRs were found, with a fold
change of 1.29 for the highest DMR.
Since DNA methylation patterns are also tissue-specific[24, 31, 32] and may be affected by
tumor localization, subgroup analyses for the two main localizations were performed: the
extremity (N = 15 pairs) and the retroperitoneum (N = 8 pairs). For the tumor samples located
in the extremity, 631 DMRs were identified between primary and recurrent samples. Also
here, no clear clustering pattern could be identified based on primary/recurrent WDLPS, time
to recurrence or the status of the resection margins (Fig 4A). For the tumor samples localized
in the retroperitoneum, 1,071 DMRs were identified. To prevent the clustering from being
blurred by background noise due to the higher number of DMRs, the clustering analysis for
the retroperitoneal tumors was based on the DMRs with a fold change >2 (N = 53 DMRs).
Again, this did not lead to a clear distinction between primary and recurrent WDLPS samples
(Fig 4B).
Discussion
To the best of our knowledge, this is the first paper comparing paired primary WDLPS sam-
ples to recurrent WDLPS samples at a molecular level. We aimed to gain more insight into the
biology of (recurrent) WDLPS and thereby the process of recurrence. The finding that no clear
distinction could be made between primary and recurrent WDPLS based on differentially
expressed microRNAs or differentially methylated DNA regions suggests that there are no
common alterations or that the alterations in microRNA expression and DNA methylation are
very heterogeneous and variable between individual patients.
In the unsupervised microRNA clustering analysis, 7 of the 13 pairs (54%) with a short time
to recurrence (before median time to recurrence) clustered together, compared to 2 of the 13
pairs (15%) with a longer time to recurrence. This might point towards a recurrence through
the outgrowth of a residue in these patients, rather than a recurrence that originates from a
28 significant differentially expressed microRNAs (p<0.05, FDR<0.25), together with time to recurrence, tumor localization, age, the status of the resection margins
and an indication of primary–recurrent pairs that cluster together. Grey designates missing expression values.
https://doi.org/10.1371/journal.pone.0228014.g001
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Fig 2. Hierarchical clustering based on the microRNA expression levels of paired primary and recurrent WDLPS tumor samples of the two main tumor
localizations. Grey designates missing expression values. (A) Results of a supervised clustering analysis based on nine differentially expressed microRNAs (p<0.05,
FDR<0.25; N = 15 pairs) between primary and recurrent WDLPS of the extremity. (B) Results of a supervised clustering analysis based on 14 differentially expressed
microRNAs (p<0.05; N = 8 pairs) between primary and recurrent WDLPS of the retroperitoneum.
https://doi.org/10.1371/journal.pone.0228014.g002
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single tumor cell. Alternatively, it might suggest that early recurrent tumors resemble each
other more closely than late recurrent tumors, because they have had less time to change.
Of the 28 differentially expressed microRNAs, miR-1263 was the most significant differen-
tially expressed microRNA, a relatively unknown microRNA whose role in cancer has not
been established yet, followed by miR-885-5p. Upregulation of this microRNA has been linked
to enhanced proliferation and migration[33], and the development of liver and lung metastases
in colorectal cancer.[34] In contrast, miR-885-5p suppressed proliferation, migration and
invasion in vitro in osteosarcoma cells, and was downregulated in osteosarcoma patients with
low expression levels being associated with a poor prognosis.[35] In our study, miR-885-5p
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Fig 3. Hierarchical clustering based on differentially methylated DNA regions (DMRs) between primary and recurrent WDLPS samples. The heat
map depicts a supervised clustering of the 27 paired WDLPS samples based on 455 differentially methylated regions (DMRs), excluding sex chromosomal
regions (N = 15 DMRs), together with the clinicopathological features time to recurrence, tumor localization, age and the status of the resection margins.
https://doi.org/10.1371/journal.pone.0228014.g003
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was downregulated in the recurrent tumors, possibly matching the findings in osteosarcoma
with low levels of miR-885-5p being associated with more proliferation and a poorer progno-
sis. Lastly, in our comparison of primary and recurrent WDLPS we did not detect differential
expression of the microRNAs that were previously found to be important for sarcomagenesis
in WDLPS, such as miR-628[6], miR-675[6], miR-26a[8], miR-451[8] or miR-193b.[28] How-
ever, these microRNAs were all discovered in comparisons with ’normal’ fat tissue.
Remarkably, only 470 DMRs with relatively low fold changes were identified between pri-
mary and recurrent WDLPS, which is a relatively small number considering the thousands of
potential DNA methylation sites in the genome. Possibly, this can be explained by the low-
grade nature of this tumor type.[1] Furthermore, there was large variability in the number of
DMRs between the pairs, ranging from 294 to 32,854 DMRs. Given our extensive efforts to
compose a homogenous dataset by selecting only WDLPS without any neoadjuvant/adjuvant
treatment and using only sections almost entirely consisting of tumor tissue, it seems that the
inter-tumor heterogeneity is abundant. This heterogeneity–in DNA methylation as well as in
microRNA expression–could also be due to intra-tumor heterogeneity, such as exists in other
cancers. The concept of intra-tumor heterogeneity describes the observation that a tumor may
exist of different tumor cells with distinct molecular and genomic profiles. If the used primary
tumor sample was taken of one part of the tumor, but the recurrence mainly consists of cells
from another part of the tumor or of cells that had a relatively small contribution to the pri-
mary tumor, this might explain the differences in microRNA expression profiles and DNA
methylation patterns, even in case of a short time to recurrence (Fig 5). However, currently it
is unknown whether such an intra-tumor heterogeneity is present in WDLPS.
Fig 4. Hierarchical clustering based on differentially methylated DNA regions (DMRs) between paired WDLPS
tumor samples for the two main localizations. (A) Results of the hierarchical supervised clustering, excluding sex
chromosomal regions (N = 27), based on 604 DMRs of the 15 paired WDLPS samples localized in the extremity. (B)
Results of the hierarchical supervised clustering analysis based on the 51 DMRs with a fold change�2, excluding sex
chromosomal regions (N = 2), of the 8 paired retroperitoneal WDLPS samples.
https://doi.org/10.1371/journal.pone.0228014.g004
Primary tumor with intra-tumor heterogeneity
leaving residual cells behind after surgery
Recurrent tumor consisting
of only one clone 
Sample used for
profiling experiments
Fig 5. Schematic overview of the concept of intra-tumor heterogeneity in the context of the current study. If the primary tumor
sample that was used for the experiments mainly consists of one specific cancer cell subtype, but the recurrent tumor is a recurrence of
mainly other cancer cell subtypes, this might explain the large variability in DNA methylation and microRNA expression, even in case
of short time to recurrence.
https://doi.org/10.1371/journal.pone.0228014.g005
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A relatively high number of DMRs occurred in chromosome 12, including DMRs linked to
MDM2, suggesting that hypermethylation of chromosome 12 plays a role in recurrence. How-
ever, with the MeD-seq method one cannot reliably discriminate copy number variations from
actual differences in DNA methylation. Since WDLPS is characterized by amplification of a
specific region on chromosome 12 (12q14-15)[1, 36], including MDM2 and CDK4 amongst
others, we cannot reliably distinguish between additional amplification or actual changes in
DNA methylation.
A limitation of the study was that in approximately a third of the patients the status of the
resection margins of the primary surgery was not specified in the pathology report. Unfortu-
nately, due to the retrospective nature of the study, which is inevitable when studying
extremely rare diseases like WDLPS, we were not able to retrieve these. However, this percent-
age (29.6%) of missing resection margins is not unusual and in line with the number (24.0%)
of pathology reports lacking information on the resection margins in a nationwide study on
sarcoma care in the Netherlands.[37] The strengths of this study were the relatively large sam-
ple size and the use of paired samples collected from multiple centers. Both microRNAs and
DNA methylation are known to vary–to a certain extent–between individuals[38, 39], and by
using paired samples, we aimed to eliminate or minimize this inter-individual variability, so
that only microRNAs and DMRs involved in sarcomagenesis would remain in the analyses.
The results of this study suggest that there are no common alterations on microRNA or
DNA methylation level that are possibly involved as drivers in the process of recurrence. The
next question is whether recurrent WDLPS has different molecular abnormalities upfront, i.e.
in the primary tumor, than those who do not recur. Therefore, for a future research project we
would recommend to compare primary WDLPS samples of patients who did not develop a
recurrence to primary WDLPS tumor samples of patients who did develop a recurrence.
Conclusion
Primary and recurrent WDLPS cannot be distinguished based on microRNA expression pro-
files and DNA methylation patterns. Although no common alterations for recurrence could be
revealed, a role for microRNAs and DNA methylation in the process of recurrence cannot be
ruled out completely, since the aberrations contributing to recurrence might be very heteroge-
neous and variable between individuals. Alternatively, other molecular events may underlie
WDLPS recurrence.
Supporting information
S1 Fig. Visualization of principal component analyses (PCA) using the microRNA expres-
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